DNA Synthesizer Market Size, Share & Trends Analysis Report By Type (Benchtop DNA Synthesizers, Large-scale DNA Synthesizers), By Application (Drug Discovery and Development, Genetic Engineering, Clinical Diagnostics), By End-User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Clinical Laboratories) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Dna Synthesizer Market Size

The global dna synthesizer market size was valued at USD 4.75 billion in 2025 and is projected to grow from USD 5.70 billion in 2026 to USD 24.51 billion by 2034, registering a CAGR of 20% during the forecast period from 2026 to 2034. North America dominated the dna synthesizer market with a market share of 38% in 2025.

The growing demand for effective DNA synthesizers from life science laboratories and pharmaceutical and biotechnology businesses is the primary driver of the DNA Synthesizer Market share.

A DNA synthesizer is a laboratory tool that automates the chemical creation of unique DNA sequences. It enables researchers to fast and precisely build oligonucleotides, or small DNA segments with specified nucleotide sequences. Solid-phase synthesis is a procedure used by DNA synthesizers in which nucleotides are sequentially added to a developing DNA chain anchored to a solid substrate, such as a resin bead. This process consists of nucleotide coupling, deprotection, and washing processes managed by automated protocols included in the synthesizer.

The market is driven by rising demand for synthetic DNA in various research and development activities, including drug discovery, gene synthesis, and molecular diagnostics. Furthermore, advances in DNA synthesis technology, such as increased efficiency, precision, and scalability, encourage researchers and biotech businesses to invest in DNA synthesizers. The growing use of personalized medicine and the demand for custom-designed DNA molecules all contribute to market growth. Furthermore, the growing field of synthetic biology, with applications in agriculture, biofuels, and industrial enzymes, is pushing demand for DNA synthesizers.

However, one key constraint is the high cost of DNA synthesis tools and consumables, which makes them unaffordable for smaller research laboratories or academic institutions with limited resources. Furthermore, the difficulty of operating DNA synthesizers and needing specialized workers can hinder adoption.

Type Insights

The benchtop DNA synthesizers category dominated the market, accounting for 70%. Factors such as increased R&D expenditure, rising need for bespoke DNA synthesis, and strong demand from a broad spectrum of end users are expected to fuel segment expansion. Furthermore, benchtop models' increased revenue share can be attributed to their cost-effectiveness. Benchtop models are smaller and less expensive than pilot-scale synthesizers, making them more suitable for small businesses and research laboratories.

Furthermore, these synthesizers are widely employed in applications such as PCR mutagenesis, gene cloning, and site-guided mutagenesis. Recent synthetic biology and genetics advances, new product launches, and favorable government laws drive greater synthesizer demand. For example, in May 2022, EVONETIX LTD reported receiving a thermally regulated DNA synthesis patent. The patented approach enables nucleic acid synthesis in a tabletop synthesizer platform.

The large-scale DNA synthesizers category is predicted to grow at a considerable CAGR throughout the forecast period. Strong demand from pharmaceutical and biotechnology industries, developments in DNA sequencing technologies, and an increasing requirement for high-throughput screening are expected to drive category expansion. Large-scale synthesizers are increasingly being used for high-throughput screening in drug development, which is expected to create attractive growth possibilities for the industry.

Request Customizationto receive a tailored report.

Application Insights

The drug discovery and development segment was the most profitable, accounting for 50% of total revenue. DNA synthesizers are essential in drug discovery processes because they enable the rapid synthesis of unique DNA sequences for target identification, validation, and lead optimization. In drug discovery, DNA synthesizers create molecular probes, gene constructs, and expression vectors to investigate gene function, protein interactions, and signaling cascades. These synthetic DNA sequences are critical for screening compound libraries, finding pharmacological targets, and creating innovative therapies in various fields, including oncology, neurology, and infectious illnesses.

Additionally, the widespread use of DNA synthesizers in drug discovery, technological advancements, increased adoption of high-throughput technologies, and many market players with extensive product portfolios are expected to drive segment expansion. Furthermore, increasing demand for improved synthesis tools from drug companies to improve efficiency is driving segment growth. Twist Bioscience, for example, revealed plans in June 2022 to use its DNA synthesis platform to reduce barriers to drug discovery. This enabled the company to increase its drug development capabilities.

The genetic engineering segment will have the quickest CAGR during the projection period. Genetic engineering manipulates and alters genetic material to produce desired organism traits or functionality. DNA synthesizers are sound in genetic engineering applications because they enable researchers to design, manufacture, and assemble custom DNA constructs for gene editing, recombinant protein expression, and metabolic engineering projects.

Additionally, advancements in genetic engineering, increased availability of gene editing tools such as CRISPR/Cas9, and more financing for commercializing innovative interventions in genetic engineering are all driving segment growth. The availability of various tiny and laboratory-scale synthesizers is also projected to drive segment expansion.

End Users Insights

The pharmaceutical and biotechnology companies segment had the most significant revenue share of 50% in 2023. Most pharmaceutical and biotechnology businesses employ synthetic DNA to generate novel genetic therapies and in the drug discovery process. Thus, the demand for synthesizers from biotechnology and pharmaceutical businesses is expected to rise dramatically in the coming years as the need for precision medicine and innovative therapeutic techniques grows.

Additionally, leading market companies prioritize developing and implementing novel platforms to boost synthesis, another driver driving sector expansion. For example, in February 2023, AstraZeneca automated its DNA synthesis capabilities to reduce costs and time. Furthermore, according to Telesis Bio, automating DNA production helps accelerate the drug discovery process. Moreover, the company stated that automation allows pharmaceutical and biotechnology companies to leverage and expand their pipelines.

The academic and research institutes segment is predicted to grow at the quickest CAGR over the forecast period. Increasing areas of interest in research, continued efforts to build novel synthesizers with higher yield capabilities, and collaboration between companies and research institutions are all likely to drive segment expansion. For example, in January 2020, Evonetix partnered with imec to promote chip-based technology manufacturing for a third-generation nucleic acid synthesis platform.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global DNA synthesizer market shareholder and is estimated to grow at a CAGR of 19.8% over the forecast period.North America held the most important market share of 40% in 2023. The existence of many market players and the different developments they have undertaken are the primary drivers of regional growth. Furthermore, technical improvements, significant investment in R&D, and increased demand for novel synthesizers all boost the regional industry. Moreover, investment by market actors in the region is growing. For example, in March 2022, Molecular Assemblies, Inc. raised USD 25.8 million in series B funding to launch a critical client program for completely enzymatic DNA synthesis.

Additionally, according to a National Institutes of Health (NIH) report from March 2023, autoimmune illnesses afflict between 23.5 and 50 million Americans, making them the third most common disease group behind cancer and heart disease. The NIH also notes that the prevalence of autoimmune biomarkers is rising in the United States. Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, has announced the acquisition of Immunetrics, Inc. ("Immunetrics"), a modeling and simulation company focused on accelerating drug development in oncology, immunology, and autoimmune diseases, three of the fastest growing therapeutic areas.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Dna Synthesizer Market Trends

Asia-Pacific is anticipated to exhibit a CAGR of 20.2% over the forecast period. This can be ascribed to a boom in interest in synthetic biology research and increased R&D efforts to produce effective therapies. Furthermore, Asia-Pacific has a high incidence of disease due to lifestyle changes. Improving healthcare infrastructure, the entry of significant biotechnology organizations, and increased market investments in this region will likely increase demand for synthesizers. In September 2022, He Jiankui, the founder of Genetically Modified Kids, requested assistance from the Chinese government in raising USD 7.2 million for a DNA synthesizer project. The project intends to create China's first third-generation DNA synthesis platform.

Furthermore, the market is experiencing an increase in commercial activities such as collaborations, acquisitions, new product launches, and investments, which is pushing the growth of the DNA synthesizer market in Asia Pacific. In December 2022, GSK, Takeda, and Sanofi partnered with the Biologics Pharma Innovation Programme to study and create cutting-edge biologics such as vaccines and recombinant proteins.

Europe is predicted to give enormous potential opportunities for DNA Synthesizer, with a high market share of 25% during the forecast period. Europe is expected to have substantial market growth owing to increased research and development for gene synthesis in vaccine preparation.

List of Key and Emerging Players in DNA Synthesizer Market